NovoCure Limited · NASDAQ:NVCR
NovoCure — Investor Presentation (January 2023)
23 slides from NovoCure's investor presentation, January 2023
Slide 1: Novocure
Novocure patient
Slide 2: Forward-looking statements
novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding a
Slide 3: Together with our patients, we strive to extend survival
Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer patientforward’ FOUNDED IN 2000, NOW 1500+ employees novecure’ 26,000+ |SSOOM+ PATIENTS TREATED ANNUAL NET REVENUES GLOBALLY TO DATE 5 ONGOING PHASE 3/4 STUDIES WITH REGISTRATIONAL INTENT. global
Slide 4: Late-stage pipeline offers substantial, near-term market expansion opportunity
novecure’ late-stage pipeline offers substantial, near-term market expansion opportunity GLIOBLASTOMA LATE-STAGE PIPELINE 14x CURRENT MARKET OPPORTUNITY PANOVA-3 Pancreatic Cancer ~35% penetration in key markets METIS Brain Metastasis ENGOT-ov50/ INNOVATE-3 ‘Ovarian Cancer @ =1,000 addressable cases
Slide 5: Tumor Treating Fields are electric fields that kill cancer cells
novocure’ Tumor Treating Fields (TTFields) are electric fields that exert physical forces to NY YY TEELDS SAN TUMOR TREATING FIELDS THERAPY kill cancer cells via a variety of mechanisms TTFields spare healthy cells because they have different properties than cancer cells across a range of tumor type
Slide 6: Optune continuous delivery system
novecure’ Optune® continuous delivery system PORTABLE MEDICAL DEVICE electric field generator and arrays TT Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
Slide 7: Tumor Treating Fields have multiple, distinct mechanisms of action
novecure’ Tumor Treating Fields have multiple, distinct mechanisms of action interference of disruption of mitosis 4 a mechanisms work cell movement lave! \ f migration together to selectively target and disrupt the progression of cancer i cells, which can lead to their death os downstream enhanceme
Slide 8: Backbone therapy potential with clinical versatility across solid tumors
novecure’ backbone therapy potential with clinical versatility across a range of solid tumors and concurrent therapies IMMUNOTHERAPY Brain — atezolizumab OO ee eae = @ pembrolizumab L my pon —_ - nivolumab ung Ra, “ ws NS SY ‘ e CHEMOTHERAPY NX ny TTT Ovarian RON aa carboplatin — ’ A . | FIELDS | [a
Slide 9: A comprehensive strategy for long-term growth
novecure’ a comprehensive strategy for long-term growth drive commercial advance deliver adoption clinical trials product innovation in approved to reach new patient to increase dose and indications populations duration of therapy Built upon a foundation of financial strength and a robust intellectu
Slide 10: An established commercial business in GBM
an established commercial business in GBM 10 ACTIVE MARKETS SWEDEN FRANCE.) GERMANY. CANADA, SWITZERLAND: AUSTRIA CHINA UNITED STATES é ‘JAPAN ISRAEL COVERED LIVES GLOBALLY 5,400+ ACTIVE PATIENTS ON THERAPY ANNUAL NET REVENUES patientforward © 2023Novocure GmbH 10
Slide 11: Multiple levers to drive net revenue growth
multiple levers to drive net revenue growth embedded in business model PAYERS ARE BILLED A SINGLE MONTHLY FEE FOR ALL SERVICES AND EQUIPMENT patient INCREASE PENETRATION IN CURRENT MARKETS DEVELOP COMPONENTS TO MAXIMIZE THERAPY AND COMFORT EXPAND INTO NEW MARKETS ENHANCE PATIENT ENGAGEMENT TO INCREA
Slide 12: Comprehensive approach to drive penetration in established markets
comprehensive approach to drive penetration in established markets patientforward STRENGTHEN HCP RECOMMENDATION Educate HCPs on benefits of TTFields therapy INCREASE PATIENT DEMAND Arm patients to advocate for Optune® STREAMLINED ORGANIZATION Creation of U.S. CNS Cancers Franchise intended to renew
Slide 13: Growing body of real-world evidence supporting TTFields
novecure’ growing body of real-world evidence supporting Statistically significant improvements in OS CBTRUS Improvements in survival for glioblastoma in the post-Stupp protocol era uv Duke University Suieeghe ee School of Medicine Corey Neff2, Mackenzie Price'?, Gordon Chavez, Christina Proeschold,
Slide 14: Holistic strategy to expand TTFields clinical footprint
holistic strategy to expand TTFields clinical footprint Investigate Expand labels use in new in approved indications L indications Explore additive effects with standards of care
Slide 15: Platform technology driving robust clinical pipeline
novecure’ platform technology driving robust clinical pipeline TRIAL TTFIELDS + | PHASE2 | _—PHASE3/4_— | _— APPROVED EF-14 temozolomide CNS newly diagnosed TRIDENT. temozolomide + radiation A glioblastoma KEYNOTE D58 temozolomide + oe program pembrolizumab panne it allobisstora EF-L1 monotherapy ee
Slide 16: Multiple randomized pivotal trials set to read out in near-term
novecure’ multiple randomized pivotal trials set to read Out in near-term | MET PRIMARY ENDPOINT | ENROLLMENT COMPLETE | LUNAR Q ENGOT-ov50/ METIS PANOVA-3 Lung Cancer IN NOVATE-3 Brain Metastasis Pancreatic Cancer Ovarian Cancer * Evaluating TTFields with * Evaluating TTFields with * Evaluating TTF
Slide 17: To be presented at a future medical congress
‘A TO BE PRESENTED AT A FUTURE MEDICAL CONGRESS ‘Trial design can be found on www clinicaltrials gov. [NCT02973789}. 0S, overall survival.
Slide 18: Planned commercial pathway to treating NSCLC patients
novecure’ planned commercial pathway to treating NSCLC patients 5 2023 C 2024 2025 L COMMERCIAL LAUNCH * Activate physician and REGULATORY PATHWAY ; ; patient education CLINICAL DATA . lates pre-PMA discussions programs r ; with FDA * Treat on-protocol patients nnounce topline results * Submit PMA &
Slide 19: Product roadmap to prioritize dose and efficacy
product roadmap to prioritize dose and efficacy field generator arrays software applications next gen device new arrays MAXPOINT™ in development treating patients through planning software limited market release in development patient © 2023Novocure GmbH 19
Slide 20: Optune proven to extend patient survival
novecure’ Optune® proven to extend patient survival EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM! Overall survival (5-year survival analysis) © Hl Optune® + TMZ (n=466) | Megan OS tron’ ne 209 16.0 os HE TMZ atone (n=229) TecventeYetie 001 yee mera petrol 5 o7 2 ” Median OStromdagnoss a4 | so.
Slide 21: Optimized dose delivered can lead to increased efficacy
novecure’ optimized dose delivered can lead to increased efficacy TUMOR TREATING FIELDS DOSE DELIVERED TIME ON xX FIELD INTENSITY xX CONDUCTIVITY om THERAPY TO TUMOR OF TISSUE —_ patientforward © 2023Novocure GmbH 21 Ballo MT, et al. Correlation of Tumor Treating Fields Dosimetry to Survival Outcome
Slide 22: New lighter, thinner arrays deliver greater intensity
novecure’ new lighter, thinner arrays deliver greater intensity EXISTING ARRAYS NEW ARRAYS AP channel, 1,364 mAmps AP channel, 1,685 mAmps In first patient use, new arrays exhibited a improvement in field intensity in tumor region versus existing arrays patientforward © 2023 Novocure GmbH 22 Acray p
Slide 23: One mission
1,500+ 9 AO+ EMPLOYEES GLOBAL OFFICES NATIONALITIES REPRESENTED one mission together with our patients, we Strive to extend survival in some of the most aggressive forms of cancer